Schering AG Sees Betaseron Pricing Flexibility Given Premium On Tysabri
This article was originally published in The Pink Sheet Daily
Executive Summary
Betaseron price increase in December still puts multiple sclerosis therapy at 30% discount to Tysabri (formerly Antegren) based on the wholesale acquisition cost. Betaseron global sales reach $1 bil. in 2004.
You may also be interested in...
Biogen Idec/Elan's Tysabri Priced At Premium To Serono/Pfizer's Rebif
With a wholesale acquisition cost of $1,808, Tysabri will sell for at least a 20% premium to Rebif. Pricing for the MS therapy reflects the expectation of future indications in Crohn's and rheumatoid arthritis.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?